Lumonus Secures A$25 Million Series B to Expand AI-Powered Radiation Oncology Platform Globally
核心洞察
Lumonus (搜索) closed a A$25 million Series B funding round led by Aviron Investment Management (搜索) to scale its AI-powered radiation oncology workflow solutions globally.
The platform has already supported clinicians in over 280,000 cancer treatments and automated creation of more than 75,000 treatment plans across health systems in the US, Australia, and Europe.
Funding will expand US commercial operations, advance flagship products Lumonus AI Physician (搜索) and AI Dosimetry, and enhance clinical informatics capabilities for personalized cancer care.
Lumonus (搜索), a leader in AI-powered radiation oncology workflow solutions, announced the completion of its A$25 million Series B financing round led by Aviron Investment Management (搜索), with continued participation from Oncology Ventures (搜索). The funding underscores strong clinical adoption of the company's AI platform across leading health systems in the United States, Australia, and Europe.
The Lumonus (搜索) AI platform has demonstrated significant clinical impact, supporting clinicians in consulting and prescribing over 280,000 cancer treatments while automating the creation of over 75,000 cancer treatment plans. This scale demonstrates the platform's effectiveness in streamlining critical oncology workflows and improving both efficiency and consistency of care delivery.
Clinical Adoption and Market Expansion
Keith Hansen, Chief Executive Officer of Lumonus (搜索), highlighted the current state of oncology care: "Oncology is at an inflection point. Scientific innovation in cancer treatment has advanced significantly, but the systems that support teams delivering the care have not kept pace." Hansen emphasized that the company's approach combines AI-native architecture with comprehensive end-to-end workflow solutions, partnering directly with care teams to address real-world challenges.
The funding will specifically support expansion of US go-to-market and clinical success teams, advancement of flagship products including Lumonus AI Physician (搜索) and Lumonus AI Dosimetry (搜索), and investment in clinical informatics capabilities. The company plans to expand partnerships with health systems to harness real-world evidence, measure quality metrics, improve operational performance, and deliver more personalized, data-driven care.
Technology Platform and Clinical Impact
Lumonus (搜索) AI operates as a digital oncology platform that transforms cancer care through AI-native clinical infrastructure. Built in partnership with leading cancer centers, the platform automates and orchestrates critical oncology workflows to improve quality, accelerate delivery, and reduce administrative burden for healthcare providers.
Merrick Howes, Chairman of Lumonus (搜索), noted the platform's proven capabilities: "Our unique AI-native platform has already demonstrated its ability to improve clinical quality and operational efficiency. This new capital will allow us to accelerate both product innovation and expand our U.S. commercial footprint."
Investment Partnership and Industry Expertise
The Lumonus (搜索) leadership team brings more than 100 years of combined clinical, operational, and technical experience from cancer centers across the United States, Europe, and APAC regions. This extensive expertise grounds the company in the practical realities of oncology care delivery and drives its mission to empower care teams with high-quality, efficient treatment solutions.
Ben Freeberg, Managing Partner at Oncology Ventures (搜索), emphasized the company's unique positioning: "The Lumonus (搜索) team combines deep clinical expertise with world-class product execution and has already earned the trust of leading cancer centers internationally. We are proud to support Lumonus as they continue to deliver measurable impact and set the standard for the future of oncology workflows."
Aviron Investment Management (搜索), which led the Series B round, specializes in healthcare and technology sectors, partnering with innovative companies leveraging technology to solve complex challenges in life sciences and health sectors. The firm has supported Lumonus (搜索) since inception, providing strategic capital and operational insight for scaling breakthrough solutions with global impact.